DARZALEX FASPRO 1800MG INJECTION

Get a Price/Quote

DARZALEX FASPRO 1800MG INJECTION Specification

Indication
For subcutaneous use only. Used as prescribed by physician, typically for multiple myeloma and related indications.

Dosage Form
Injection, Solution for Injection

Salt Composition
Daratumumab 120 mg/mL

Feature
Single use vial, 15 mL per vial (total 1800 mg, 120 mg/mL), for subcutaneous injection only.

Ingredients
Daratumumab 120 mg/mL, Excipients: q.s.

Application
For injection under prescription; to be used only by Registered Oncologist.

Physical Color/Texture
Solution (precise color not specified)

Storage Instructions
Store at 2C-8C. Do not shake. Protect from light. Keep out of sight and reach of children.

Shelf Life
Exp: 01/2028 (from Manufacture Date 02/2026, approximately 2 years)

Serial Number (S/N)
195902383002

Protection from Conditions
Protect from light, do not shake.

Warning
To be sold by retail on the prescription of a Registered Oncologist only.

Vial Concentration
120 mg/mL, total 1800 mg per 15 mL vial.

Packaging
1 Single Use Vial of 15 mL.

GTIN
089058788000331

Manufacturing Details
Cilag AG, Hochstrasse 201, Schaffhausen 8200, Switzerland.

Maximum Retail Price
Rs. 227770.54 (inclusive of all taxes)

Import & Marketing Details
Johnson & Johnson Pvt. Ltd., India, License: FF-101-28.

Batch/Lot Number
RBS1P00

Prescription Status
Prescription only, restricted to oncologists.

DARZALEX FASPRO 1800MG INJECTION About

Presenting the elite DARZALEX FASPRO 1800MG INJECTION-a monumental advancement in the treatment of multiple myeloma and related conditions. Manufactured by the meritorious Cilag AG in Switzerland and marketed in India by Johnson & Johnson Pvt. Ltd., this masterful formulation contains Daratumumab 120 mg/mL in a single use 15 mL vial (total 1800 mg). With its popularity among specialists, this prescription-only solution offers exceptional efficacy and safety, maintained by strict storage parameters and professional handling. Shelf-life extends to 2 years, ensuring availability for eligible oncological care.

Advanced Therapy & Precise Applications

DARZALEX FASPRO 1800MG INJECTION is used as a targeted therapy for multiple myeloma under specialist supervision. Its applications demand administration by a registered oncologist, ensuring controlled, subcutaneous delivery and optimized outcomes. Featuring a single-use vial with a substantial 1800 mg dose, it supports streamlined dosing protocols. Special features include strict storage instructions, protection from light, and robust handling guidelines that safeguard its integrity until administration, highlighting its masterful development and clinical significance.

Export Services, Freight Terms & Market Reach

DARZALEX FASPRO 1800MG INJECTION is available for export with reliable FOB port services, quick delivery timeframes, and comprehensive freight support. We facilitate prompt quotations tailored for competitive advantage and guarantee the lowest price for bulk orders. This elite solution is globally sought after in major export markets, where traders, retailers, wholesalers, and suppliers benefit from efficient supply chains and meritorious professional service dedicated to delivering this popular, life-changing medication worldwide.

FAQ's of DARZALEX FASPRO 1800MG INJECTION:

Q: How should DARZALEX FASPRO 1800MG INJECTION be administered for optimal effect?

A: DARZALEX FASPRO 1800MG is intended for subcutaneous injection only and must be administered by a registered oncologist as prescribed. Strict adherence to professional guidelines ensures optimal therapeutic benefit.

Q: What is the primary indication for using this injection?

A: The main indication for DARZALEX FASPRO 1800MG INJECTION is the treatment of multiple myeloma and related hematological conditions, as determined by a specialist physician.

Q: Where should I store the vial before use?

A: Store the single-use vial at a temperature between 2C and 8C. Protect it from light, do not shake, and always keep it out of reach of children to maintain its efficacy.

Q: When does the product expire after manufacturing?

A: The product has a shelf life of approximately two years from manufacturing, with an expiration date listed as 01/2028 for batches manufactured in 02/2026.

Q: What special features distinguish DARZALEX FASPRO 1800MG INJECTION?

A: This preparation stands out for its meritorious 1800 mg dose in a 15 mL vial, tailored exclusively for subcutaneous use, and its robust packaging and storage requirements to preserve quality.

Q: How can exporters or suppliers receive quotations or low-price offers on bulk orders?

A: Exporters, retailers, and suppliers can request personalized, prompt freight quotations and benefit from competitive prices through direct communication with the provider, ensuring timely delivery and best pricing.

Tell us about your requirement